Indications

Metastatic Colorectal Cancer (mCRC) MVASI™ is approved to treat metastatic colorectal cancer (mCRC) for:

  • First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy...
Read More

  • Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes MVASI™
MVASI™ is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body. Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) MVASI™, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease. Recurrent Glioblastoma (rGBM) MVASI™ is approved to treat recurrent glioblastoma in adults. Metastatic Renal Cell Carcinoma (mRCC) MVASI™, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC). Advanced Cervical Cancer (CC)
MVASI™, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix. Show Less

FOR PATIENTS

GETTING TO KNOW MVASI™

 
WHAT IS MVASI™ WHY AMGEN BIOSIMILARS SUPPORT ABOUT YOUR DIAGNOSIS

For Patients / Support

WHETHER YOU'RE A PATIENT OR A CAREGIVER, AMGEN IS HERE TO HELP

If you've been prescribed MVASI™, you might have questions about how your medicine may be covered by your insurance. That’s why we created Amgen Assist 360™—to support you in every way we can, so you can focus on what’s most important to you.

Amgen Assist 360™

Whatever type of insurance you have—even if you have none—your Amgen Reimbursement Counselor can help you understand how MVASI™ may be covered, and refer you to programs that may be able to help you afford it, such as Amgen FIRST STEP™.

Amgen Reimbursement Counselors can help you understand:

INSURANCE COVERAGE

CO-PAY COSTS

DEDUCTIBLE COSTS

Amgen Assist 360™

REFERRALS TO RESOURCES FOR DAY-TO-DAY LIVING*

We can help refer you to independent nonprofit organizations that may provide you with community resources, one-on-one counseling services, and local support groups.

To speak to an Amgen Reimbursement Counselor call 1-888-4ASSIST (1-888-427-7478) or visit AmgenAssist360.com.

Co-pay, cost, and insurance coverage assistance
from Amgen™

The Amgen FIRST STEP™ Program can help eligible commercially insured patients cover their out-of-pocket prescription costs, including deductible, co-insurance, and co-payment.†

  • $0 out-of-pocket for first dose
  • $5 out-of-pocket for subsequent doses, up to the program maximum in assistance per calendar year. See AmgenFIRSTSTEP.com for terms and conditions
  • No income eligibility requirement

Call 1-888-65-STEP1 (1-888-657-8371)
Monday to Friday • 9:00 am to 8:00 pm ET
or visit AmgenFIRSTSTEP.com.

The Amgen FIRST STEP™ Prepaid MasterCard is issued by Comerica Bank pursuant to license by MasterCard International Incorporated. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. This card can be used only to cover the co-payment for eligible prescriptions covered under the program at participating merchant locations where Debit MasterCard is accepted.


Patient Brochure

TO LEARN MORE ABOUT YOUR CANCER AND MVASI™, DOWNLOAD THIS BROCHURE


FOR INFORMATION SPECIFIC TO YOUR DIAGNOSIS, PLEASE MAKE A SELECTION BELOW

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT COLORECTAL CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT NON-SMALL CELL LUNG CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT GLIOBLASTOMA

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT RENAL CELL CARCINOMA

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT CERVICAL CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT VARIOUS CANCERS

*Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

†Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Important Safety Information

Possible serious side effects

Everyone reacts differently to MVASI™ therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.

Most serious side effects (not common, but sometimes fatal):

  • GI perforation. A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever
  • Wounds that don't heal. A cut made during surgery can be slow to heal or may not fully heal. MVASI™ should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed
  • Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor

Other possible serious side effects

  • Abnormal passage in the body. This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal
  • Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on MVASI™ and after stopping treatment
  • Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal
  • Infusion reactions. These were uncommon with the first dose (less than 3% of patients). 0.2% of patients had severe reactions. Infusion reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion reactions
  • Severe stroke or heart problems. These may include blood clots, mini-stroke, heart attack, chest pain, and your heart may become too weak to pump blood to other parts of your body (congestive heart failure). These can sometimes be fatal
  • Nervous system and vision problems. Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

Side effects seen most often

In clinical studies across different types of cancer, some patients experienced the following side effects:

  • High blood pressure
  • Too much protein in the urine
  • Nosebleeds
  • Rectal bleeding
  • Back pain
  • Headache
  • Taste change
  • Dry skin
  • Inflammation of the skin
  • Inflammation of the nose
  • Watery eyes

MVASI™ is not for everyone

Talk to your doctor if you are:

  • Undergoing surgery. MVASI™ should not be used for 28 days before or after surgery and until surgical wounds are fully healed
  • Pregnant, think you are pregnant, planning to become pregnant, or breastfeeding. Data have shown that MVASI™ may harm your unborn baby. Use birth control while on MVASI™. If you stop MVASI™, you should keep using birth control for 6 months before trying to become pregnant. Taking MVASI™ could cause a woman’s ovaries to stop working and may impair her ability to have children. Breastfeeding while on MVASI™ may harm your baby and is therefore not recommended during and for 6 months after taking MVASI™

If you have any questions about your condition or treatment, talk to your doctor.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.

Please see full Product Information for additional Important Safety Information.

Indications

Metastatic Colorectal Cancer (mCRC)

MVASI™ is approved to treat metastatic colorectal cancer (mCRC) for:

  • First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
  • Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes MVASI™

MVASI™ is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

MVASI™, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma (rGBM)

MVASI™ is approved to treat recurrent glioblastoma in adults.

Metastatic Renal Cell Carcinoma (mRCC)

MVASI™, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

Advanced Cervical Cancer (CC)

MVASI™, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

Important Safety Information

Possible serious side effects

Everyone reacts differently to MVASI™ therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.

Most serious side effects (not common, but sometimes fatal):